Could Innovate Biopharmaceuticals, Inc. (INNT) Gain Strenght? The Stock Reaches 52-Week Low

April 18, 2018 - By Adrian Erickson

The stock of Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) is a huge mover today! The stock decreased 16.81% or $5.05 during the last trading session, reaching $25. About 419,476 shares traded or 24.96% up from the average. Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) has risen 147.01% since April 18, 2017 and is uptrending. It has outperformed by 135.46% the S&P500.
The move comes after 6 months negative chart setup for the $642.29 million company. It was reported on Apr, 18 by Barchart.com. We have $24.25 PT which if reached, will make NASDAQ:INNT worth $19.27 million less.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. The company has market cap of $642.29 million. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH). It currently has negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: